Eyexora Launches With Bold Mission To Reshape Global Ophthalmology Innovation

KUALA LUMPUR, Sept 11 (Bernama) -- Eyexora, a global ophthalmology company, has launched the first ophthalmology company built on a hub-and-spoke model, aiming to accelerate drug and device development on a global scale.

Backed by seed financing led by ClavystBio and supported by leading ophthalmology experts, Eyexora enters the market with assets in-licensed from the Singapore Eye Research Institute (SERI) and early collaborations across Singapore and Europe.

“Traditional ophthalmology drug development has been dominated by single-asset pipelines, making innovation slow, costly, and high-risk.

“Eyexora is built to change that by bringing the right structure, global partnerships, and deep domain expertise together to deliver transformative treatments faster, smarter, and at scale,” said Eyexora Chief Executive Officer (CEO), Dr Theresa Heah in a statement.

The company overcomes the inefficiencies of traditional drug development by centralising scientific, clinical, regulatory, and commercial expertise in a shared operational “hub” that deploys across its subsidiaries, in which each subsidiary houses a distinct therapeutic or technology programme, enabling scalable growth while reducing risk.

The model is designed to balance validated mechanisms with high-impact “moonshots”, replenished with clinic-ready assets sourced from global clinician-scientists and academic incubators.

Co-founded by ophthalmology leaders with decades of combined industry experience, Eyexora Chairman, Dr Bill Link is a renowned ophthalmology investor and entrepreneur, having founded Versant Ventures, AMO, and Flying-L Partners.

Meanwhile, its Vice Chair, CEO and Co-Founder, Dr Heah has held senior leadership positions at Aerie Pharmaceuticals, Kriya, AGTC, Sanofi-Fovea, and Bayer and is recognised for her proven track record in late-stage ophthalmic drug development.

-- BERNAMA